Gain Therapeutics, Inc. (GANX) stock
GANXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.18+0.24 (+25.51%)
Close on Nov 17, 2026Market cap $51.50MP/E –Yield –
Gain Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Gain Therapeutics's profit margin for the twelve months ending Dec 31, 2023 was -40354.3%. For fiscal 2023 it was -40354.3%, against -12555.1% the year before.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | -40354.3% | −27799.2 |
| FY2022 | Dec 31, 2022 | -12555.1% | −4136.3 |
| FY2021 | Dec 31, 2021 | -8418.9% | +3968.8 |
| FY2020 | Dec 31, 2020 | -12387.7% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2023 | Mar 31, 2023 | -9310.1% | +7744.3 |
| Q2 FY2022 | Jun 30, 2022 | -5347.3% | −1358.8 |
| Q1 FY2022 | Mar 31, 2022 | -7271.6% | +39235.3 |
| Q4 FY2021 | Dec 31, 2021 | -7452.2% | +10664.5 |
| Q3 FY2021 | Sep 30, 2021 | -17054.4% | −5191.1 |
| Q2 FY2021 | Jun 30, 2021 | -3988.5% | +4537.5 |
| Q1 FY2021 | Mar 31, 2021 | -46506.9% | −37751.2 |
| Q4 FY2020 | Dec 31, 2020 | -18116.7% | – |
| Q3 FY2020 | Sep 30, 2020 | -11863.4% | – |
| Q2 FY2020 | Jun 30, 2020 | -8526.0% | – |
| Q1 FY2020 | Mar 31, 2020 | -8755.7% | – |
See a number that looks wrong?